JP2016509023A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016509023A5 JP2016509023A5 JP2015558092A JP2015558092A JP2016509023A5 JP 2016509023 A5 JP2016509023 A5 JP 2016509023A5 JP 2015558092 A JP2015558092 A JP 2015558092A JP 2015558092 A JP2015558092 A JP 2015558092A JP 2016509023 A5 JP2016509023 A5 JP 2016509023A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- polypeptide
- variant
- npp4
- npp1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims description 190
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 152
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 152
- 229920001184 polypeptide Polymers 0.000 claims description 147
- 101150011046 NPP1 gene Proteins 0.000 claims description 69
- 101100080092 Phytophthora capsici NLP1 gene Proteins 0.000 claims description 69
- 230000000694 effects Effects 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 32
- 230000007062 hydrolysis Effects 0.000 claims description 31
- 238000006460 hydrolysis reaction Methods 0.000 claims description 31
- 230000035772 mutation Effects 0.000 claims description 24
- 108010064470 polyaspartate Proteins 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- QCICUPZZLIQAPA-XPWFQUROSA-N P(1),P(3)-bis(5'-adenosyl) triphosphate Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1COP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 QCICUPZZLIQAPA-XPWFQUROSA-N 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 8
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 8
- 235000011180 diphosphates Nutrition 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000035475 disorder Diseases 0.000 claims description 8
- 229920000805 Polyaspartic acid Polymers 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000000816 peptidomimetic Substances 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- -1 small molecule chemical compounds Chemical class 0.000 claims description 5
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 claims description 4
- 208000004434 Calcinosis Diseases 0.000 claims description 4
- 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 claims description 4
- 208000034970 Heterotopic Ossification Diseases 0.000 claims description 4
- 101150071357 NPP2 gene Proteins 0.000 claims description 4
- 101100080097 Phytophthora capsici NLP2 gene Proteins 0.000 claims description 4
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 claims description 4
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 230000001575 pathological effect Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 claims description 3
- 208000009469 Ossification of Posterior Longitudinal Ligament Diseases 0.000 claims description 3
- 235000011941 Tilia x europaea Nutrition 0.000 claims description 3
- 208000005475 Vascular calcification Diseases 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims description 3
- 239000004571 lime Substances 0.000 claims description 3
- 201000002044 ossification of the posterior longitudinal ligament of spine Diseases 0.000 claims description 3
- 208000001040 ossification of the posterior longitudinal ligament of the spine Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000013543 active substance Substances 0.000 claims 4
- 230000004913 activation Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 102100021961 Bis(5'-adenosyl)-triphosphatase ENPP4 Human genes 0.000 description 55
- 101000897056 Homo sapiens Bis(5'-adenosyl)-triphosphatase ENPP4 Proteins 0.000 description 55
- 238000000034 method Methods 0.000 description 37
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019135862A JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764297P | 2013-02-13 | 2013-02-13 | |
| US61/764,297 | 2013-02-13 | ||
| US201361904786P | 2013-11-15 | 2013-11-15 | |
| US61/904,786 | 2013-11-15 | ||
| PCT/US2014/015945 WO2014126965A2 (en) | 2013-02-13 | 2014-02-12 | Compositions and methods for treating pathological calcification and ossification |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019135862A Division JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016509023A JP2016509023A (ja) | 2016-03-24 |
| JP2016509023A5 true JP2016509023A5 (OSRAM) | 2017-02-16 |
| JP6894664B2 JP6894664B2 (ja) | 2021-06-30 |
Family
ID=51354667
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015558092A Active JP6894664B2 (ja) | 2013-02-13 | 2014-02-12 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2019135862A Active JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2021104071A Active JP7420766B2 (ja) | 2013-02-13 | 2021-06-23 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2024002210A Pending JP2024026704A (ja) | 2013-02-13 | 2024-01-11 | 病的な石灰化および骨化を治療するための組成物および方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019135862A Active JP6944977B2 (ja) | 2013-02-13 | 2019-07-24 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2021104071A Active JP7420766B2 (ja) | 2013-02-13 | 2021-06-23 | 病的な石灰化および骨化を治療するための組成物および方法 |
| JP2024002210A Pending JP2024026704A (ja) | 2013-02-13 | 2024-01-11 | 病的な石灰化および骨化を治療するための組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US9744219B2 (OSRAM) |
| EP (2) | EP2956163B1 (OSRAM) |
| JP (4) | JP6894664B2 (OSRAM) |
| ES (1) | ES3014398T3 (OSRAM) |
| PL (1) | PL2956163T3 (OSRAM) |
| WO (1) | WO2014126965A2 (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014126965A2 (en) * | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| USRE49529E1 (en) | 2014-12-19 | 2023-05-16 | Inozyme Pharma, Inc. | Methods of treating tissue calcification |
| EP3298140B1 (en) | 2015-05-19 | 2024-04-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
| US20180371434A1 (en) * | 2015-11-20 | 2018-12-27 | Yale University | Compositions for Treating Ectopic Calcification Disorders, and Methods Using Same |
| EP3471747A1 (en) * | 2016-06-16 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Methods of treating myointimal proliferation |
| AU2017306549A1 (en) * | 2016-08-05 | 2019-02-21 | Yale University | Compositions and methods for stroke prevention in pediatric sickle cell anemia patients |
| EP3687565A1 (en) | 2017-09-27 | 2020-08-05 | Alexion Pharmaceuticals, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) |
| WO2019217373A1 (en) * | 2018-05-08 | 2019-11-14 | Yale University | Compositions and methods for reducing progression of nephrolithiasis |
| CN120383683A (zh) * | 2018-08-31 | 2025-07-29 | 耶鲁大学 | Enpp1多肽及其使用方法 |
| BR112022024958A2 (pt) | 2020-06-09 | 2022-12-27 | Inozyme Pharma Inc | Proteínas enpp1 solúveis e usos das mesmas |
| CN116322742A (zh) * | 2020-07-02 | 2023-06-23 | 依诺兹梅制药公司 | 用于治疗同种异体移植物血管病、烟雾病、烟雾病综合征和内膜增殖的组合物和方法 |
| WO2022076848A1 (en) * | 2020-10-08 | 2022-04-14 | Inozyme Pharma, Inc. | Liver specific production of enpp1 or enpp3 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
| US5190931A (en) | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5168053A (en) | 1989-03-24 | 1992-12-01 | Yale University | Cleavage of targeted RNA by RNAase P |
| US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
| US6043056A (en) | 1998-11-06 | 2000-03-28 | Incyte Pharmaceuticals, Inc. | Cell surface glycoproteins |
| US20020183276A1 (en) * | 2001-03-23 | 2002-12-05 | Burnham Institute | Compositions and methods for modulating bone mineral deposition |
| US7888372B2 (en) | 2001-03-23 | 2011-02-15 | National Institutes Of Health (Nih) | Compositions and methods for modulating bone mineral deposition |
| WO2003016475A2 (en) | 2001-08-14 | 2003-02-27 | The General Hospital Corporation | Nucleic acid and amino acid sequences involved in pain |
| AU2003213246A1 (en) | 2002-02-21 | 2003-09-09 | University Of Virginia Patent Foundation | Bone targeting peptides |
| GB0803352D0 (en) | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| WO2011113027A2 (en) * | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
| KR101772366B1 (ko) | 2011-03-11 | 2017-08-28 | 알렉시온 파마슈티칼스, 인코포레이티드 | Ｎｐｐ１ 융합 단백질 |
| WO2014126965A2 (en) * | 2013-02-13 | 2014-08-21 | Yale University | Compositions and methods for treating pathological calcification and ossification |
| USRE49529E1 (en) * | 2014-12-19 | 2023-05-16 | Inozyme Pharma, Inc. | Methods of treating tissue calcification |
| EP3298140B1 (en) | 2015-05-19 | 2024-04-24 | Yale University | Compositions for treating pathological calcification conditions, and methods using same |
-
2014
- 2014-02-12 WO PCT/US2014/015945 patent/WO2014126965A2/en not_active Ceased
- 2014-02-12 EP EP14751154.7A patent/EP2956163B1/en active Active
- 2014-02-12 US US14/765,514 patent/US9744219B2/en active Active
- 2014-02-12 PL PL14751154.7T patent/PL2956163T3/pl unknown
- 2014-02-12 ES ES14751154T patent/ES3014398T3/es active Active
- 2014-02-12 EP EP24215211.4A patent/EP4523757A3/en active Pending
- 2014-02-12 JP JP2015558092A patent/JP6894664B2/ja active Active
-
2017
- 2017-03-22 US US15/466,401 patent/US9913881B2/en active Active
- 2017-08-08 US US15/671,287 patent/US20170333533A1/en not_active Abandoned
- 2017-08-25 US US15/686,972 patent/US10052367B2/en active Active
-
2018
- 2018-07-12 US US16/033,948 patent/US10624958B2/en active Active
-
2019
- 2019-07-24 JP JP2019135862A patent/JP6944977B2/ja active Active
-
2020
- 2020-03-09 US US16/813,315 patent/US11266722B2/en active Active
-
2021
- 2021-06-23 JP JP2021104071A patent/JP7420766B2/ja active Active
-
2022
- 2022-01-28 US US17/587,253 patent/US20220152163A1/en active Pending
-
2024
- 2024-01-11 JP JP2024002210A patent/JP2024026704A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016509023A5 (OSRAM) | ||
| JP7320571B2 (ja) | 筋消耗疾患治療用の新規なハイブリッドａｃｔｒｉｉｂリガンド捕集タンパク質 | |
| KR102401869B1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
| US20220332791A1 (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| JP7715635B2 (ja) | イズロン酸２－スルファターゼを含むタンパク質分子の製剤 | |
| TWI573806B (zh) | 生物活性胜肽 | |
| RU2017144183A (ru) | Композиции для лечения патологических состояний кальцификации и способы их применения | |
| AU2014293386B2 (en) | Cyclic polypeptides for the treatment of heart failure | |
| AU2018201073A1 (en) | Therapeutic nuclease compositions and methods | |
| JP2016527249A (ja) | 合成アペリンポリペプチドのバイオコンジュゲート | |
| US20240150736A1 (en) | Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof | |
| JP2017521425A (ja) | インフルエンザウイルスワクチンおよびその使用 | |
| US20250325469A1 (en) | Inhibitors of atp synthase - cosmetic and therapeutic uses | |
| TW201425339A (zh) | 用於治療心臟衰竭之合成線狀愛帕琳（ａｐｅｌｉｎ）模擬物 | |
| WO2008047370A3 (en) | Compositions and methods for inducing angiogenesis | |
| JP6615504B2 (ja) | 高血圧症の予防又は治療用医薬 | |
| JP2008531463A5 (OSRAM) | ||
| JP2011515471A5 (OSRAM) | ||
| TWI748306B (zh) | 包含人類Lefty A蛋白變體的融合蛋白及其用途 | |
| CN117651564A (zh) | 脑血管事件和神经系统疾病的治疗 | |
| Balboni et al. | Influence of the side chain next to C-terminal benzimidazole in opioid pseudopeptides containing the Dmt-Tic pharmacophore | |
| RU2793631C2 (ru) | Слитый белок, содержащий варианты человеческого белка lefty а, и его применение | |
| ES2353479T3 (es) | Moduladores de il-32. | |
| WO2016011003A1 (en) | TGFβ TYPE II-TYPE III RECEPTOR FUSIONS | |
| JP7756367B2 (ja) | 変異型ａｃｅ２タンパク質 |